The eradication ofHelicobacter pyloriinfection is still a challenge for clinicians. Approximately 5% of patients who undergo two courses of eradication therapy remain infected. The authors of this Viewpoint article discuss the available options for salvage therapy in these patients and the role of antimicrobial susceptibility testing in this setting.
- Lorenzo Fuccio
- Rocco Maurizio Zagari
- Franco Bazzoli
